Loading...
Loading...
KYTHERA Biopharmaceuticals
KYTH today announced positive
interim results from a Phase IIIb, multi-center, open-label study
(ATX-101-11-26) to evaluate the safety and efficacy of ATX-101, an
investigational injectable drug for the reduction of unwanted submental
fat (SMF), commonly known as double chin. The results, presented at the
Late Breaking Research Symposium at the 71st American Academy
of Dermatology (AAD) Annual Meeting in Miami Beach, Fla., found that
ATX-101 is well-tolerated and may be effective in reducing SMF by both
clinician and patient reported outcome measures. The ATX-101 global
clinical development program has enrolled more than 2,500 total
patients, of which more than 1,500 have been treated with ATX-101.
“In my practice, patients often
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in